Johnson & Johnson (JNJ) Position Decreased by Capital Investment Services of America Inc.
Capital Investment Services of America Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 3.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,954 shares of the company’s stock after selling 450 shares during the period. Capital Investment Services of America Inc.’s holdings in Johnson & Johnson were worth $1,581,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Lenox Wealth Advisors Inc. increased its holdings in Johnson & Johnson by 0.7% in the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new position in Johnson & Johnson in the 1st quarter worth about $186,000. Taylor Wealth Management Partners increased its holdings in Johnson & Johnson by 19.8% in the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Foundation Resource Management Inc. acquired a new position in Johnson & Johnson in the 1st quarter worth about $204,000. 65.90% of the stock is owned by institutional investors and hedge funds.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.
Johnson & Johnson (NYSE JNJ) traded down 0.25% during midday trading on Tuesday, reaching $135.04. The company had a trading volume of 1,781,902 shares. The company has a 50-day moving average price of $132.72 and a 200-day moving average price of $129.35. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The stock has a market capitalization of $362.45 billion, a price-to-earnings ratio of 22.85 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter in the prior year, the business earned $1.74 EPS. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.48%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.
A number of equities analysts have issued reports on JNJ shares. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Royal Bank Of Canada reissued a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 15th. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a research note on Friday, July 21st. Jefferies Group LLC reissued a “hold” rating and issued a $145.00 price target (up previously from $140.00) on shares of Johnson & Johnson in a research note on Friday, July 14th. Finally, Morgan Stanley increased their price target on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average price target of $134.50.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.